Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.
about
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approachPharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measurePharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticusDrug metabolism and interactions in abuse liability assessment.A review of psychophysiological stressors on pharmacokinetics.The effects of fall-risk-increasing drugs on postural control: a literature review.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Effect of Extracorporeal Membrane Oxygenation Use on Sedative Requirements in Patients with Severe Acute Respiratory Distress Syndrome.Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers.Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteersLack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected].Modulation of human corticomotor excitability by somatosensory input.Cortical excitability changes induced by deafferentation of the contralateral hemisphere.Relationship between cerebral pharmacokinetics and anxiolytic activity of diazepam and its active metabolites after a single intra-peritoneal administration of diazepam in mice.Lorazepam induces an atypical dissociation of visual and auditory event-related potentials.Population Pharmacokinetic/ Pharmacodynamic Modelling of Auditory-Evoked Event-Related Potentials with Lorazepam.Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam.
P2860
Q24652176-DA127706-C2FD-42D7-86CE-B9456D91AC4FQ34055606-29BCF5BD-2315-4A8F-8D31-54F792B9D933Q35742520-B960486B-142C-4665-BE84-C4AFBF732412Q36941534-AE385BFF-07B7-4715-BD70-A5FCE7A0ABEEQ37831732-63B05BDC-56E2-49B8-9E2B-C7E1B7F46FBAQ38134320-CB341788-0153-450B-9F0C-C79729D5D856Q38204833-B4899B4D-17BA-46C2-B725-26DC8D403E7FQ39808379-1365A1FC-AB3C-48FF-94DB-04FDACFFFA8BQ40643023-AE693EEE-2BBD-4943-8149-F9E6DFE519C3Q41596586-C5E40C3A-3A1A-4A2B-9462-159206A6D90DQ41853785-CBA93542-3B5C-4969-8975-1D788759CF3CQ43684625-C6BACBBE-56F3-4723-AB8C-4966C06C83F3Q43961432-E8C9ED25-6D4A-4D1F-B14E-373EC67DFCAAQ44002220-0F058F4B-349E-47F9-B668-C5A973A10162Q44197194-B252C694-32CC-4875-828B-368656417E01Q44393711-D487BAB5-10A1-4C45-B6C8-D3D76C34D383Q48127960-F8B1EC01-FB0C-4198-A9B9-7CBB1775DD05Q49158629-8F71816D-EDB7-40BB-AD42-DB2696B42DAA
P2860
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@en
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@nl
type
label
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@en
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@nl
prefLabel
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@en
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@nl
P2093
P2860
P356
P1476
Simultaneous modeling of the p ...... benzodiazepines. I: Lorazepam.
@en
P2093
A M Nikaido
D G Heatherly
E H Ellinwood
P2860
P2888
P304
P356
10.1007/BF01063553
P577
1990-04-01T00:00:00Z